Literature DB >> 12372129

A comparative study of eicosanoid concentrations in sputum and urine in patients with aspirin-intolerant asthma.

N Higashi1, M Taniguchi, H Mita, M Osame, K Akiyama.   

Abstract

BACKGROUND: Although many studies have assumed that the overproduction of cysteinyl- leukotrienes (cys-LTs) and an imbalance of arachidonic acid metabolism may be plausible causes for the pathogenesis of aspirin-intolerant asthma (AIA), there has been little experimental evidence to substantiate this notion in lower airways of patients with AIA.
OBJECTIVES: The purpose of this study was to compare the eicosanoid concentrations in sputum and urine from patients with AIA.
METHODS: The concentrations of sputum cys-LTs, prostaglandin E2 (PGE2), PGF2alpha, PGD2 and thromboxane B2 were measured to assess local concentrations of eicosanoids in patients with AIA and in those with aspirin-tolerant asthma (ATA). The concentrations of two urinary metabolites, leukotriene E4 (LTE4) and 9alpha11betaPGF2, were also measured to corroborate the relationship between the eicosanoid biosynthesis in the whole body and that in lower airways.
RESULTS: The concentration of PGD2 in sputum was significantly higher in patients with AIA than in those with ATA (median, 5.3 pg/mL vs. 3.1 pg/mL, P < 0.05), but there was no significant difference in the concentration of the corresponding metabolite, 9alpha11betaPGF2, between the two groups. No differences were noted in the concentrations of other prostanoids in sputum between the two groups. The sputum cys-LT concentrations showed no differences between the two groups, in spite of the observation that the concentration of urinary LTE4 was significantly higher in patients with AIA than in those with ATA (median, 195.2 pg/mg-cre vs. 122.1 pg/mg-cre, P < 0.05). There was a significant correlation among the concentration of cys-LTs, the number of eosinophils and the concentration of eosinophil-derived neurotoxin (EDN) in sputum.
CONCLUSION: The urinary concentration of LTE4 does not necessary reflect cys-LT biosynthesis in lower airways. A significantly higher concentration of PGD2 in sputum from patients with AIA suggests the possible ongoing mast cell activation in lower airways.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12372129     DOI: 10.1046/j.1365-2745.2002.01507.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  11 in total

Review 1.  Mass Spectrometry-based Metabolomics in Translational Research.

Authors:  Su Jung Kim; Ha Eun Song; Hyo Yeong Lee; Hyun Ju Yoo
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Leukotrienes and airway inflammation.

Authors:  Katsuhide Okunishi; Marc Peters-Golden
Journal:  Biochim Biophys Acta       Date:  2011-02-23

Review 3.  New concepts for the pathogenesis and management of aspirin-exacerbated respiratory disease.

Authors:  Esha Sehanobish; Mohammad Asad; Elina Jerschow
Journal:  Curr Opin Allergy Clin Immunol       Date:  2022-02-01

Review 4.  Aspirin-induced asthma: clinical aspects, pathogenesis and management.

Authors:  Ahmed M Hamad; Amy M Sutcliffe; Alan J Knox
Journal:  Drugs       Date:  2004       Impact factor: 9.546

5.  Aspirin activation of eosinophils and mast cells: implications in the pathogenesis of aspirin-exacerbated respiratory disease.

Authors:  John W Steinke; Julie Negri; Lixia Liu; Spencer C Payne; Larry Borish
Journal:  J Immunol       Date:  2014-06-02       Impact factor: 5.422

6.  Exhaled Eicosanoids following Bronchial Aspirin Challenge in Asthma Patients with and without Aspirin Hypersensitivity: The Pilot Study.

Authors:  L Mastalerz; M Sanak; J Kumik; A Gawlewicz-Mroczka; N Celejewska-Wójcik; A Cmiel; A Szczeklik
Journal:  J Allergy (Cairo)       Date:  2012-01-12

Review 7.  Hypersensitivity to Aspirin and other NSAIDs: Diagnostic Approach in Patients with Chronic Rhinosinusitis.

Authors:  Joanna Makowska; Anna Lewandowska-Polak; Marek L Kowalski
Journal:  Curr Allergy Asthma Rep       Date:  2015-08       Impact factor: 4.806

8.  9α,11β-PGF2, a Prostaglandin D2 Metabolite, as a Marker of Mast Cell Activation in Bee Venom-Allergic Patients.

Authors:  Marita Nittner-Marszalska; Ewa Cichocka-Jarosz; Marek Sanak; Magdalena Wujczyk; Anna Dor-Wojnarowska; Grzegorz Lis; Jerzy Liebhart
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2015-03-13       Impact factor: 4.291

Review 9.  Potential Biomarkers for NSAID-Exacerbated Respiratory Disease.

Authors:  Hanki Park; Youngwoo Choi; Chang-Gyu Jung; Hae-Sim Park
Journal:  Mediators Inflamm       Date:  2017-08-09       Impact factor: 4.711

Review 10.  Aspirin Actions in Treatment of NSAID-Exacerbated Respiratory Disease.

Authors:  Esha Sehanobish; Mohammad Asad; Mali Barbi; Steven A Porcelli; Elina Jerschow
Journal:  Front Immunol       Date:  2021-06-25       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.